Efficacy, safety, and tolerability of remibrutinib (LOU064) in CSU patients: Study design of phase 3B extension trial

被引：0
|
作者：
Maurer, M. [1 ,2 ,3 ,4 ]
Gimenez-Arnau, A. M. [5 ]
Saini, S. [6 ]
Lebwohl, M. [7 ]
Sussman, G. [8 ]
Hide, M. [9 ,10 ]
Lheritier, K. [11 ]
Zharkov, A. [11 ]
Bhat, S. [12 ]
Wei, L. [13 ]
Martzloff, E. D. [11 ]
Haemmerle, S. [11 ]
机构：
[1] UCARE, Inst Allergol, Berlin, Germany
[2] Freie Univ, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
[4] Fraunhofer Inst Translat Med & Pharmacol ITMP, Berlin, Germany
[5] Univ Pompeu Fabra, Hosp Mar IMIM, Dept Dermatol, Barcelona, Spain
[6] Johns Hopkins Univ, Div Allergy & Clin Immunol, Sch Med, Baltimore, MD USA
[7] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA
[8] Univ Toronto, Div Allergy & Clin Immunol, Toronto, ON, Canada
[9] Hiroshima Univ, Dept Dermatol, Hiroshima, Japan
[10] Hiroshima Citizens Hosp, Dept Dermatol, Hiroshima, Japan
[11] Novartis Pharma AG, Basel, Switzerland
[12] Novartis Healthcare Pvt Ltd, Hyderabad, India
[13] China Novartis Inst Biomed Res Co Ltd, Shanghai, Peoples R China
来源：
ALLERGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
000937
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus
    Pavel, Marianne
    Unger, Nicole
    Borbath, Ivan
    Ricci, Sergio
    Hwang, Tsann-Long
    Brechenmacher, Thomas
    Park, Jinhee
    Herbst, Fabian
    Beaumont, Jennifer L.
    Bechter, Oliver
    TARGETED ONCOLOGY, 2016, 11 (05) : 667 - 675
  • [32] Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus
    Marianne Pavel
    Nicole Unger
    Ivan Borbath
    Sergio Ricci
    Tsann-Long Hwang
    Thomas Brechenmacher
    Jinhee Park
    Fabian Herbst
    Jennifer L. Beaumont
    Oliver Bechter
    Targeted Oncology, 2016, 11 : 667 - 675
  • [33] Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: Results of a phase 3b study
    Burton, Barbara K.
    Nowacka, Maria
    Hennermann, Julia B.
    Lipson, Mark
    Grange, Dorothy K.
    Chakrapani, Anupam
    Trefz, Friedrich
    Dorenbaum, Alex
    Imperiale, Michael
    Kim, Sun Sook
    Fernhoff, Paul M.
    MOLECULAR GENETICS AND METABOLISM, 2011, 103 (04) : 315 - 322
  • [34] Rationale and Design of a Phase 3b Study of the Long-Term Tolerability and Safety of HyQvia in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): ADVANCE-CIDP 3
    Hasan, Shabbir
    Duff, Kimberly
    Wisseh, Steve
    Youssef, Ashraf
    Chavan, Shailesh
    NEUROLOGY, 2020, 94 (15)
  • [35] Efficacy, safety, and tolerability of fesoterodine in patients with overactive bladder: A phase 3 placebo controlled trial in the United States
    Nitti, VW
    Dmochowski, RR
    Williams, T
    Alvarez-Jacinto, OR
    JOURNAL OF UROLOGY, 2006, 175 (04): : 57 - 57
  • [36] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Puig, Luis
    Lebwohl, Mark
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Gomez, Natalie Nunez
    Eyerich, Kilian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : 486 - 495
  • [37] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial
    Lebwohl, Mark
    Ghoreschi, Kamran
    Strober, Bruce
    Eyerich, Kilian
    Cather, Jennifer
    Wang, Maggie
    Cioffi, Christopher
    Deherder, Delphine
    Staelens, Fabienne
    Gomez, Natalie Nunez
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB145 - AB145
  • [38] Safety and tolerability of conversion to siponimod with and without titration in patients with advancing forms of relapsing multiple sclerosis: interim results of the phase 3b EXCHANGE study
    Bar-Or, A.
    Weinstock-Guttman, B.
    Mao-Draayer, Y.
    Cruz, L. -A.
    Meng, X.
    Cox, G. M.
    Cohan, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 574 - 575
  • [39] TRIAL DESIGN FOR PHASE 3 FALCON: EVALUATION OF THE SAFETY, TOLERABILITY, AND EFFICACY OF BARDOXOLONE METHYL IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
    Chapman, Arlene
    Appel, Gerald B.
    Block, Geoffrey A.
    Chin, Melanie P.
    Goldsberry, Angie
    Meyer, Colin J.
    O'Grady, Megan
    Rastogi, Anjay
    Silva, Arnold
    Tesar, Vladimir
    Pergola, Pablo E.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2021, 77 (04) : 583 - 583
  • [40] Safety and efficacy results from an international phase 3b study for expanded access to Bortezomib in patients with relapsed and/or refractory multiple myeloma
    Mikhael, J.
    Belch, A.
    Prince, M.
    Lucio, M. Nambo
    Maiolino, A.
    Corso, A.
    Petrucci, M. T.
    Musto, P.
    Komarnicki, M.
    Stewart, A. K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 164 - 164
12345